InvestorsObserver
×
News Home

Is Ionis Pharmaceuticals Inc (IONS) Stock a Bad Value Monday?

Monday, January 24, 2022 02:44 PM | InvestorsObserver Analysts

Mentioned in this article

Is Ionis Pharmaceuticals Inc (IONS) Stock a Bad Value Monday?

Ionis Pharmaceuticals Inc (IONS) is near the bottom in its sector according to InvestorsObserver. IONS gets an overall rating of 10. That means it scores higher than 10% of stocks. Ionis Pharmaceuticals Inc gets a 21 rank in the Healthcare sector. Healthcare is number 11 out of 11 sectors.

Overall Score - 10
IONS has an Overall Score of 10. Find out what this means to you and get the rest of the rankings on IONS!

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies in the healthcare sector can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the best stocks in that sector. These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With Ionis Pharmaceuticals Inc Stock Today?

Ionis Pharmaceuticals Inc (IONS) stock is up 1.2% while the S&P 500 is lower by -2.51% as of 2:44 PM on Monday, Jan 24. IONS has gained $0.36 from the previous closing price of $29.88 on volume of 1,003,459 shares. Over the past year the S&P 500 is higher by 11.21% while IONS is lower by -52.59%. IONS lost -$4.23 per share the over the last 12 months. Click Here to get the full Stock Report for Ionis Pharmaceuticals Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App